SecurityMDVX / Medovex Corp. (58504H101)
IndustrySurgical and Medical Instruments and Apparatus
Common Shares Outstanding23,376,526 shares (as of 2018-03-31)
Total Insiders16
Total Directors11
Total Officers5

Stock Insider Trading (from SEC Form 4)

Medovex Corp. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

MDVX / Medovex Corp. insiders include Kullmann Patrick C, and Hills Thomas Edward Gorlin Jarrett S, Sablowski Manfred, PAPASAN LARRY W, Haufe Scott, Crowne Jesse, Betz Randal R, Wright Jeffery Scott, Lawson James Ronald JR, Hennies Clyde A., Moon Dennis Glenn, Thomas John C, ANDREWS JAMES R M D, GORLIN STEVE, Mogford Jon, .

Insider Roster

Insider Dir Off 10% Shares Owned
Crowne Jesse Director
X 210,747
Betz Randal R Director
X 181,027
Thomas John C Director
X 115,960
Mogford Jon Director
X 16,840
ANDREWS JAMES R M D Director
X 131,348
Hennies Clyde A. Director
X 131,348
GORLIN STEVE
1,640,704
Haufe Scott Director
X 1,031,782
Lawson James Ronald JR Director
X 18,256
PAPASAN LARRY W Director
X 228,136
Gorlin Jarrett S CHIEF EXECUTIVE OFFICER, Director
X X 662,172
Moon Dennis Glenn EXECUTIVE VICE PRESIDENT
X
Sablowski Manfred VP OF SALES AND MARKETING
X
Kullmann Patrick C COO, PRESIDENT
X
Wright Jeffery Scott CHIEF FINANCIAL OFFICER
X
Hills Thomas Edward Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-01-11 4 Crowne Jesse A D 0.550 10,407 210,747
2018-01-03 4 Crowne Jesse A D 0.550 4,093 200,340
2017-12-29 4 Betz Randal R A D 0.521 350 181,027
2017-12-29 4 Betz Randal R A D 0.558 9,650 180,677
2017-12-15 4 Mogford Jon P D 0.70 -1,000 16,840 11,788
2017-12-15 4 Thomas John C P D 0.70 -6,000 115,960 81,172
2017-10-30 4 Thomas John C A D 1.17 12,821 109,960
2017-10-30 4 PAPASAN LARRY W A D 1.17 12,821 228,136
2017-10-30 4 Mogford Jon A D 1.17 12,821 15,840
2017-10-30 4 Betz Randal R A D 1.17 12,821 164,837
2017-10-30 4 Lawson James Ronald JR A D 1.17 12,821 18,256
2017-10-30 4 Haufe Scott A D 1.17 12,821 1,031,782
2017-10-30 4 Crowne Jesse A D 1.08 31,240 200,340
2017-10-30 4 Crowne Jesse A D 1.17 2,137 169,100
2017-10-30 4 GORLIN STEVE A D 1.17 10,684 1,640,704
2017-10-30 4 Hennies Clyde A. A D 1.17 12,821 131,348
2017-10-30 4 ANDREWS JAMES R M D A D 1.17 12,821 131,348
2017-09-19 4 Haufe Scott S D 1.18 -20,000 1,018,961 1,202,374
2017-09-18 4 Haufe Scott S D 1.19 -50,000 1,038,961 1,236,364
2017-08-21 4 GORLIN STEVE P D 1.25 50,000 1,630,020 2,037,525
2017-08-16 4 GORLIN STEVE P D 0.90 200,000 1,580,020 1,422,018
2017-07-14 4 Betz Randal R P D 0.91 10,989 152,016 138,335
2017-06-28 4 GORLIN STEVE P D 0.88 2,000 1,380,020 1,214,418
2017-06-28 4 GORLIN STEVE P D 0.87 3,000 1,378,020 1,198,877
2017-06-19 4 Gorlin Jarrett S P D 0.90 20,000 662,172 595,955
2017-06-14 4 GORLIN STEVE P D 0.97 5,000 1,375,020 1,333,769
2017-06-07 4 GORLIN STEVE P D 0.98 5,000 1,370,020 1,342,620
2017-06-07 4 GORLIN STEVE P D 0.96 5,000 1,365,020 1,310,419
2017-06-07 4 GORLIN STEVE P D 0.95 15,000 1,360,020 1,292,019
2017-06-07 4 GORLIN STEVE P D 0.94 5,000 1,345,020 1,264,319
2017-06-06 4 Gorlin Jarrett S P D 0.94 5,000 642,172 603,642
2017-06-06 4 Gorlin Jarrett S P D 0.92 5,000 637,172 586,198
2017-06-06 4 Gorlin Jarrett S P D 0.91 5,000 632,172 575,277
2017-06-06 4 Gorlin Jarrett S P D 0.90 5,000 627,172 564,455
2017-06-06 4 Gorlin Jarrett S P D 0.89 5,000 622,172 553,733
2017-04-18 4 Haufe Scott P D 1.25 50,000 1,088,961 1,361,201
2017-03-28 4 Haufe Scott P D 1.29 250,612 1,038,961 1,340,260
2017-02-09 4 Gorlin Jarrett S P D 1.04 67,307 617,172 641,859
2017-02-09 4 GORLIN STEVE P D 1.04 144,230 1,340,020 1,393,621
2017-01-12 4 PAPASAN LARRY W A D 1.38 21,739 217,815
2017-01-12 4 Thomas John C A D 1.38 21,739 97,139
2017-01-12 4 Betz Randal R A D 1.38 21,739 141,027
2017-01-12 4 Haufe Scott A D 1.38 21,739 826,847
2017-01-12 4 Hennies Clyde A. A D 1.38 21,739 121,027
2017-01-12 4 Lawson James Ronald JR A D 1.38 5,435 5,435
2017-01-12 4 Mogford Jon A D 1.38 3,019 3,019
2017-01-12 4 ANDREWS JAMES R M D A D 1.38 21,739 121,027
2016-12-01 4 GORLIN STEVE P D 1.75 314,286 1,018,592 1,782,536
2016-12-01 4 GORLIN STEVE P D 1.75 -257,143 704,360 1,232,630
2016-04-19 4 Gorlin Jarrett S P D 1.225 44,081 561,118 687,370
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Your Daily Pharma Scoop: AEterna Zentaris Gets FDA Nod, Valeant Finalizes Sprout Sale, Roche Gets EC Approval

2017-12-21 seekingalpha
Today we will focus on the much anticipated FDA decision on AEterna Zentaris’ (AEZS) Macrilen for diagnosis of adult growth hormone deficiency. (150-5)

Your Daily Pharma Scoop: Synergy's New CEO, AbbVie Data, TiGenix Changes

2017-12-21 seekingalpha
Today we will discuss an article on Synergy Pharmaceuticals (SGYP) by John Engle, titled, “Synergy’s New CEO: More Of The Same Or Change Of Course?” (496-2)